Provectus Biopharmaceuticals (PVCT) CEO gets 8% convertible note

Rhea-AI Filing Summary

Provectus Biopharmaceuticals, Inc. CEO and director Edward Pershing reported an insider transaction dated 12/11/2025 involving an 8% unsecured convertible promissory note. This note is treated as a derivative security linked to the company’s Series D-1 Convertible Preferred Stock.

Pershing may elect at any time to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. If he does not act earlier, the note will automatically convert into Series D-1 Preferred Stock twelve months after its issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted sooner according to its terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	12/11/2025		A		$45,000		12/11/2025	12/11/2026	Series D-1 Convertible Preferred Stock(1)(2)	15,724	$0	$1,465,000	D

Explanation of Responses:

1. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing.

2. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

	/s/ Edward Pershing	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVCT report for CEO Edward Pershing?

Provectus Biopharmaceuticals (PVCT) reported that CEO and director Edward Pershing entered into a derivative transaction on 12/11/2025 involving an 8% unsecured convertible promissory note tied to the company’s Series D-1 Convertible Preferred Stock.

What are the key terms of Edward Pershing’s 8% convertible note with PVCT?

The filing states that the 8% unsecured convertible promissory note can be converted by Pershing at any time into Series D-1 Convertible Preferred Stock at a price of $2.862 per share. If he does not convert earlier, the note will automatically convert into Series D-1 Preferred Stock twelve months after its issue date.

How does PVCT’s Series D-1 Convertible Preferred Stock convert into common stock?

Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus Biopharmaceuticals common stock. The Series D-1 Preferred Stock will automatically convert into common stock on June 26, 2026, unless it is converted into common stock earlier under its terms.

What is the relationship of the reporting person to Provectus Biopharmaceuticals (PVCT)?

The reporting person, Edward Pershing, is identified as both a director and an officer of Provectus Biopharmaceuticals, serving in the role of CEO, and the form is filed by one reporting person.

How is this PVCT insider transaction classified on the SEC form?

The transaction is reported in Table II for derivative securities, describing the 8% unsecured convertible promissory note and its ability to convert into Series D-1 Convertible Preferred Stock, which in turn is convertible into common stock under the stated terms.